WO2010062103A2 - Topical skin composition and method for preparing same - Google Patents

Topical skin composition and method for preparing same Download PDF

Info

Publication number
WO2010062103A2
WO2010062103A2 PCT/KR2009/006960 KR2009006960W WO2010062103A2 WO 2010062103 A2 WO2010062103 A2 WO 2010062103A2 KR 2009006960 W KR2009006960 W KR 2009006960W WO 2010062103 A2 WO2010062103 A2 WO 2010062103A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
extract
parts
composition
stone
Prior art date
Application number
PCT/KR2009/006960
Other languages
French (fr)
Korean (ko)
Other versions
WO2010062103A3 (en
WO2010062103A9 (en
Inventor
양근영
Original Assignee
Yang Gean Yung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Gean Yung filed Critical Yang Gean Yung
Publication of WO2010062103A2 publication Critical patent/WO2010062103A2/en
Publication of WO2010062103A9 publication Critical patent/WO2010062103A9/en
Publication of WO2010062103A3 publication Critical patent/WO2010062103A3/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/22Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489Sophora, e.g. necklacepod or mamani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/756Phellodendron, e.g. corktree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/925Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof

Definitions

  • the present invention relates to an external composition for skin, and more particularly, to an external skin composition having an advantage of being effective in skin diseases such as atopic dermatitis, athlete's foot, eczema, and having low side effects and recurrence.
  • the external skin composition is an effective composition for skin diseases, and is a composition showing an effective effect on atopic dermatitis, athlete's foot, eczema and the like among skin diseases.
  • Atopic dermatitis is an abnormality in the stratum corneum, the outermost protective wall of the skin.
  • the main symptoms of atopic dermatitis are erythema, edema / papulation, and oozing / crust. ), Epidermal peeling, lichenification and dryness.
  • Atopic dermatitis takes the stages of infancy and infancy, and symptoms of infancy begin at two to three months of age, with reddening and rashes on the face, spreading to the whole frozen soup, neck, limbs and whole body. do. About 75% of infantile atopic dermatitis is lost in two stones, but about 25% of infants develop childhood atopic dermatitis and sometimes develop new ones.
  • atopic dermatitis mainly consists of pharmacotherapy such as steroids, antihistamines and antibiotics.
  • Steroids have anti-inflammatory and immunosuppressive effects and have excellent effects, but are often relapsed when discontinued, and long-term use is known to have side effects such as skin atrophy, vasodilation, discoloration, and purpura.
  • the technical problem to be achieved by the present invention is to provide an external composition for skin effective in skin diseases such as atopic dermatitis, less side effects, and low recurrence.
  • Another technical problem to be achieved by the present invention is to provide a method for producing an external composition for skin effective in atopic dermatitis and the like, less side effects and low recurrence.
  • the present invention is an external skin composition
  • an anatomical stone alum, green spots, sensitized stone, yongnae, changja extract, red ginseng extract, cheoncho extract, baekbaek extract, ginseng extract, gentamicin, dipropionate betamethasone, and badger oil
  • an anatomical stone alum, green spots, sensitized stone, yongnae, changja extract, red ginseng extract, cheoncho extract, baekbaek extract, ginseng extract, gentamicin, dipropionate betamethasone, and badger oil
  • Anatomical stone (pumex) in the composition of the present invention is a porous silicate mineral ([SiO 2 ] x) formed by the solidification of rocks spewed from volcanoes, which are essential minerals calcium, iron, zinc, copper, nickel, It contains chromium, cobalt, vanadium, and selenium. It is known to cure swelling by treating lumps and bumps on the skin and extreme abdominal pain.
  • Alumen in the composition of the present invention is a double salt formed by sulfates of monovalent metals such as alkali metals, thallium, and ammonium other than aluminum sulfate and lithium, and is also called alum.
  • monovalent metals such as alkali metals, thallium, and ammonium other than aluminum sulfate and lithium
  • substitution of other trivalent metal ions is also called alum in a broad sense, and is known to be effective for hemostasis, bleeding, insecticidal detoxification, convergence, antibacterial, trichomonas vaginitis, and liquor improvement.
  • Melanterium of the composition of the present invention is a sulfate mineral containing monoclinic ferric sulfate, the main component is ferrous sulfate (FeSO 4 ⁇ 7H 2 O), moisture, insecticide, It is known to have an effect such as blood.
  • Calamina ( ⁇ ⁇ ; Calamina) of the composition of the present invention has been described as having the efficacy of nominal, probationary, salty, lichen, baptismal, detoxification, etc. in synonym.
  • Borneol ( ⁇ ; Borneol) in the composition of the present invention has been described as having the efficacy of saengjong, blue heat pain, etc. in synonym.
  • Changzai extract in the composition of the present invention as a solvent extract of Changza, Xanthii Fructus is described in the synonym as having a potency, such as mountain breeze, insecticide, pain, detoxification.
  • the ginseng extract of the composition of the present invention is a solvent extract of the ginseng, and the ginseng ( ⁇ ⁇ ) (Sophorae Radix) has been described as having the effect of the insecticidal insects, chungpung insect, blue heat humidity.
  • Cheoncho extract in the composition of the present invention is a solvent extract of Cheoncho, Cheoncho ( ⁇ ; Zanthoxhli Pericarpium) has been described as having the efficacy of insecticide, dehumidification pain, etc. in synonym.
  • the sulfur extract of the composition of the present invention is a solvent extract of sulfur white, sulfur white ( ⁇ ; Phellodendri Cortex) has been described as having the effects of detoxification, blue heat humidity, etc. in synonym.
  • the gall bladder extract of the composition of the present invention is a gall bladder solvent extract, the gall bladder ( ⁇ ; Galla Rhois) has been described as having the effect of hemostasis, detoxification, etc. in synonym.
  • Gentamicin sulfate in the composition of the present invention is a sulfate of an aminoglycoside-based compound having antibacterial activity, and is used to treat seborrheic dermatitis, fungus or virus secondaryly infected with primary skin infections such as infectious impetigo and purulent bacteria. It is used for the treatment of secondary skin infections such as duplicate infection caused by infection.
  • Betamethasone Dipropionate in the composition of the present invention is an anti-inflammatory corticosteroid, a compound of formula C 28 H 37 FO 7 , and has a therapeutic effect such as psoriasis, seborrheic dermatitis, irritable dermatitis, contact dermatitis, eczema, etc. Known.
  • Badger oil (Melis Sebum) of the composition of the present invention is known to have the effect of lubrication, swelling detoxification, etc., in addition to the skin protective action in the composition of the present invention acts as a base and can penetrate the skin.
  • the gentamicin sulfate, dipropionate betamethasone, and badger oil may be purchased or manufactured from commercially available products.
  • the dissected stones, alum, green spots, sensitized stones, and chalcedony can be pulverized and used in powder form.
  • the particle size of the powder is 300 to 500 mesh. That is, it is possible to use a powder that passes through the mesh 300 mesh sieve and does not pass through the 500 mesh sieve.
  • the fine particles having a particle diameter of 500 mesh sieve may be absorbed by the skin or may block pores, and the coating particles may not have good coating feeling.
  • the extract may be extracted with water or an organic solvent, or a mixed solvent thereof.
  • the organic solvent may be any solvent that can be used in general, preferably a polar solvent such as water, C1-4 alcohol (for example, methanol, ethanol and the like) or a mixture thereof.
  • the extraction can be carried out by conventional methods such as hot water extraction, it can be used by lyophilizing the extract.
  • the extract can be used more purified by conventional fractionation or chromatography.
  • composition of the present invention has an effect on skin diseases, and has an effective effect on atopic dermatitis, athlete's foot, eczema and the like.
  • the present invention provides a method for improving atopic dermatitis and administering the composition to a subject.
  • the composition of the present invention is 50 to 200 parts by weight of the alum, 50 to 200 parts by weight, 50 to 200 parts by weight, 50 to 200 parts by weight of the sensitized stone, 50 to 200 parts by weight of the chalcedony extract 50 ⁇ 200 parts by weight, the ginseng extract 50 ⁇ 200 parts by weight, the Cheoncho extract 25 ⁇ 200 parts by weight, the baekbaek extract 50 ⁇ 200 parts by weight, the gall bladder extract 50 ⁇ 200 parts by weight, the gentamicin sulfate 0.1 ⁇ 1 parts by weight 5 to 20 parts by weight of the dipropionate betamethasone, and 4000 to 16000 parts by weight of the badger oil.
  • Changzai extract, Gosam extract, cheoncho extract, yellowish white extract, and quinine extract in the composition of the present invention may be a mixed extract extracted by mixing Changja, red ginseng, cheoncho, baekbaek, and quintet, dissecting the composition comprising the mixed extract 50 to 200 parts by weight of the alum, 50 to 200 parts by weight of the green spot, 50 to 200 parts by weight of the sensitized stone, 50 to 200 parts by weight of the bracts, 225 to 1000 parts by weight of the mixed extract, the sulfuric acid It may be 0.1 to 1 parts by weight of gentamicin, 5 to 20 parts by weight of the betamethasone dipropionate, and 4000 to 16000 parts by weight of the badger oil.
  • composition of the present invention in addition to the above-mentioned effective ingredient, may further include a substance exhibiting additional atopic dermatitis improving action known in the art.
  • composition of the present invention may be applied to the human body in various ways or forms, but is preferably applied topically to the skin, and has an external skin formulation. That is, ointments, gels, creams, linings, lotions, liquids, or aerosols.
  • composition of the present invention may be a pharmaceutical composition.
  • the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers may be used by mixing one or more of lactose, dextrose, sucrose, starch, saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and the like. If desired, other conventional additives such as antioxidants, buffers, bacteriostatics, stabilizers, etc. may be added. Diluents, dispersants, surfactants, solvents, disintegrants, sweeteners, binders, coatings, swelling agents, lubricants, lubricants or flavoring agents may additionally be added. Furthermore, it may be preferably formulated according to each disease or component by any suitable method in the art or using methods disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.
  • composition of the present invention when formulated into an ointment, in addition to the composition of the present invention can be prepared by appropriately mixing the ointment, other additives and the like.
  • the ointment and other additives may be appropriately selected from higher fatty acids or esters thereof, lead, surfactants, higher alcohols, silicone oils, hydrocarbons, water, humectants, and anti-infective agents.
  • the pharmaceutical composition of the present invention is by parenteral administration, preferably topical application by application.
  • the pharmaceutical composition of the present invention may be prepared in an external dermal formulation, i.e. powder, gel, ointment, cream, liquid or aerosol formulation.
  • the dosage of the active ingredient may be adjusted within the range of 0.1 mg / kg to 1000 mg / kg based on an adult weight of 60 kg.
  • the optimum dosage to be administered can be easily determined by those skilled in the art, and the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, general health of the patient It may be adjusted according to various factors including the condition, sex and diet, time of administration, and the rate of secretion of the composition, the duration of treatment, and the drugs used simultaneously.
  • composition of the present invention may be a cosmetic composition.
  • the cosmetic composition of the present invention may include components conventionally included in the cosmetic composition, and may include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, carriers, and the like.
  • conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, carriers, and the like.
  • the cosmetic composition may be prepared in any of the formulations conventionally prepared, and may be prepared, for example, as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, cleansing, spray, or the like.
  • the present invention comprises the steps of (a) pulverizing anatomical stone, alum, green spots, sensitized stone, and chalcedony; (b) distilling Changja, red ginseng, cheoncho, baekbaek, and gallengja in water and then heating to obtain a hot water extract; (c) mixing gentamicin sulfate, betamethasone dipropionate, and badger oil to obtain a mixture; And (d) mixing the ground powder of step (a), the hot water extract of step (b), and the mixture of step (c).
  • the production method of the present invention is as follows, anatomical stone, alum, green spot, sensitized stone, chalcedony, changja, red ginseng, cheoncho, baekbaek, galleng, gentamicin sulfate, dipropionate betamethasone, and badger
  • the content of oil is the same as in the composition of the present invention.
  • a pulverized product having a particle size of 300 to 500 mesh can be produced.
  • the window of step (b) was prepared by heating the mature fruit of Xanthium strumarium L. at 120 to 170 ° C. for 10 to 40 minutes to remove thorns, and the root of the ginseng (Sophora flavescens AIT.) After washing with water, it is immersed in rice water for 8 to 12 hours, it can be prepared by drying for 20 to 40 days at 10-30 °C temperature.
  • the hot water extract in the step (b) is Changja, Gosam, Cheoncho, Yellow and White, and five ginseng in a weight ratio of 50 to 200: 50 to 200: 25 to 200: 50 to 200: 50 to 200, and then mixed with respect to the mixture After immersing the mixture in purified water having a volume ratio of 3-7 times, the mixture is heated at 90-120 ° C. for 4-6 hours, the solids are filtered off, and heated and concentrated at 90-120 ° C. for 4-6 hours. .
  • Badger oil in step (c) may be prepared by heating the fat of badger at a temperature of 500 ⁇ 800 °C 1.5 ⁇ 4 hours, the mixture of step (c) is a gentamicin sulfate, dipropionate betamethasone, and badger oil It may be mixed in a weight ratio of 0.1 to 1: 5 to 20: 4000 to 16000. Badger oil may be added in step (d) to match the total amount of the composition.
  • the hot water extract mixed in step (d) may be 225 to 1000 parts by weight based on 100 parts by weight of the anatomical stone of step (a).
  • the mixing of the steps (c) and (d) may be mixed using a known mixer, etc., and after the step (d), the finished product may be manufactured by further packaging the product.
  • composition of the present invention is effective in skin diseases such as atopic dermatitis, athlete's foot, eczema, and has the advantage of low side effects and low recurrence. Moreover, the composition of this invention can be manufactured effectively by the manufacturing method of this invention.
  • Example 1 is a photograph of the skin condition before using the composition of Example 1.
  • Figure 2 is a photograph of the skin condition after using the composition of Example 1 for 5 months.
  • the window was used to remove the burned thorns by heating the dog nose to 170 °C for 25 minutes in a pan.
  • the ginseng was washed with the root of the ginseng, immersed in rice water for 10 hours, and then used to dry for 30 days at 25 ⁇ 28 °C.
  • Example 2 Comparison by mixing the extract prepared in the same manner as the extract preparation method of Example (1-2) and the badger oil (the remaining amount so that the final composition is a total of 500g) prepared in the same manner as the badger oil of Example (1-3) The composition of Example 2 was prepared.
  • a composition of Comparative Example 4 was prepared in the same manner as in Example 1, except that gentamicin sulfate and betamethasone dipropionate were not used.
  • Example 1 100 patients (5-50 years old male and female) suffering from atopic dermatitis were tested for atopic dermatitis improvement effect for 4 weeks using the composition of Example 1 and the compositions of Comparative Examples 1-5.
  • the composition of Example 1 was to be used for 50 people, each of the compositions of Comparative Examples 1 to 5 was to be used for 10 people, three times a day to spread thinly on the affected area. If the symptom disappeared during the test, it was no longer used.
  • Equation 1 The improvement rate for each individual was calculated by Equation 1 below, and the average improvement rate was obtained by dividing the total improvement rate for each individual by the number of subjects (Equation 2). The results are shown in Table 1.
  • % Improvement ⁇ (Sum of 6 items before use-Sum of 6 items after use) / Sum of 6 items before use ⁇ ⁇ 100 (%)
  • Average improvement rate (% / person) total improvement rate (%) ⁇ number of people (person)
  • Example 1 has an excellent effect of improving atopic dermatitis compared to the cases of Comparative Examples 1 to 5.
  • Example 1 17 patients with athlete's foot and 20 patients with eczema were used for athlete's foot and eczema, and the symptoms were reported to be improved.
  • Example 1 50 of the subjects using the composition of Example 1 was used for the composition of Example 1 in the same manner for an additional 4 to 5 months until complete cured, 6 months after cure if atopic dermatitis recurrence and side effects was investigated. As a result, a case of recurrence or side effects of atopic dermatitis was not investigated.
  • FIGS. 1 and 2 One of the subjects who used the composition of Example 1 for 5 months was photographed before and after 5 months of use, and the results are shown in FIGS. 1 and 2.
  • 1 is a photograph of the skin condition before use
  • Figure 2 is a photograph of the skin condition after 5 months of use. As a result, it can be confirmed that atopic dermatitis is improved by using the composition of Example 1.
  • composition of the present invention is effective in atopic dermatitis and the like, and has no problem of recurrence or side effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided are a topical skin composition and a method for preparing same, the composition comprising pumice, alum, iron sulfate, calamine, borneol, Xanthii Fructus extract, Sophorae Radix extract, Radix Rubiae extract, Phellodendri Cortex extract, Rhus gall extract, gentamycin sulfate, betamethasone dipropionate and badger oil. The composition of the present invention is effective for such skin diseases as atopic dermatitis, athlete's foot, and eczema, and has an advantage of a low risk of adverse reaction and relapse. The composition of the present invention may be effectively prepared by the preparation method of the present invention.

Description

피부외용 조성물 및 그 제조방법External skin composition and preparation method thereof
본 발명은 피부외용 조성물에 관한 것으로, 구체적으로 아토피성 피부염, 무좀, 습진 등의 피부질환에 효과적이며, 부작용과 재발가능성이 낮은 장점을 갖는 피부외용 조성물 및 그 제조방법에 관한 것이다.The present invention relates to an external composition for skin, and more particularly, to an external skin composition having an advantage of being effective in skin diseases such as atopic dermatitis, athlete's foot, eczema, and having low side effects and recurrence.
피부외용 조성물은 피부질환에 효과적인 조성물로, 피부질환 중 아토피성 피부염, 무좀, 습진 등에 유효한 효과를 나타내는 조성물이다.The external skin composition is an effective composition for skin diseases, and is a composition showing an effective effect on atopic dermatitis, athlete's foot, eczema and the like among skin diseases.
아토피성 피부염(atopic dermatitis)은 피부 가장 바깥에 있는 보호벽인 각질층에 이상이 생긴 것으로, 아토피성 피부염의 주된 증상은 홍반(Erythema), 부종/구진(Edema/Papulation), 삼출/가피(Oozing/Crust), 표피박리(Excoriation), 태선화(Lichenification), 건조(Dryness) 등이다.Atopic dermatitis is an abnormality in the stratum corneum, the outermost protective wall of the skin. The main symptoms of atopic dermatitis are erythema, edema / papulation, and oozing / crust. ), Epidermal peeling, lichenification and dryness.
급성기는 표피 내에 수포를 형성하며, 만성기는 인설과 피부의 비후가 생긴다. 아토피성 피부염은 제1기 영아기와 제2기 소아기의 단계를 취하며, 영아기의 증상은 생후 2~3개월에 시작하여 얼굴이 붉어지고 진물이 나며 얼국 전체, 목, 팔다리, 그리고 전신으로 번지기도 한다. 유아기 아토피성 피부염의 약 75%는 두 돌 안에 소실되나, 약 25%의 유아는 소아기의 아토피성 피부염으로 진행되며 새로이 발병하는 경우도 있다.The acute phase forms blisters in the epidermis, while the chronic phase develops thickening of the skin and skin. Atopic dermatitis takes the stages of infancy and infancy, and symptoms of infancy begin at two to three months of age, with reddening and rashes on the face, spreading to the whole frozen soup, neck, limbs and whole body. do. About 75% of infantile atopic dermatitis is lost in two stones, but about 25% of infants develop childhood atopic dermatitis and sometimes develop new ones.
현재까지 아토피 피부염에는 스테로이드제, 항히스타민제, 항생제 등과 같은 약물요법이 주로 이루어지고 있다. 스테로이드제의 경우 소염작용과 면역억제 작용이 있고 효과가 우수하지만 사용 중단시 재발하는 경우가 많으며, 장기간 사용할 경우 피부 위축, 혈관확장, 탈색, 자반 등의 부작용이 있는 것으로 알려져 있다.To date, atopic dermatitis mainly consists of pharmacotherapy such as steroids, antihistamines and antibiotics. Steroids have anti-inflammatory and immunosuppressive effects and have excellent effects, but are often relapsed when discontinued, and long-term use is known to have side effects such as skin atrophy, vasodilation, discoloration, and purpura.
따라서, 아토피성 피부염 등의 피부질환에 우수한 효과를 나타내며, 재발가능성이 낮고, 부작용이 적은 조성물의 개발이 요구되고 있다. 본 발명의 발명가는 오랜 시간 동안 연구 노력한 끝에 본 발명을 완성하게 되었다.Therefore, there is a demand for the development of a composition having excellent effects on skin diseases such as atopic dermatitis, low recurrence, and low side effects. The inventor of the present invention has completed the present invention after a long time research effort.
따라서, 본 발명이 이루고자 하는 기술적 과제는 아토피성 피부염 등의 피부질환에 효과적이며, 부작용이 적고, 재발가능성이 낮은 피부외용 조성물을 제공하고자 하는 것이다.Therefore, the technical problem to be achieved by the present invention is to provide an external composition for skin effective in skin diseases such as atopic dermatitis, less side effects, and low recurrence.
또한, 본 발명이 이루고자 하는 다른 기술적 과제는 아토피성 피부염 등에 효과적이며, 부작용이 적고 재발가능성이 낮은 피부외용 조성물의 제조방법을 제공하고자 하는 것이다.In addition, another technical problem to be achieved by the present invention is to provide a method for producing an external composition for skin effective in atopic dermatitis and the like, less side effects and low recurrence.
한편, 본 발명의 명시되지 않은 또 다른 목적들은 하기의 상세한 설명 및 그 효과로부터 용이하게 추론할 수 있는 범위 내에서 추가적으로 고려될 것이다.On the other hand, other unspecified objects of the present invention will be further considered within the range that can be easily inferred from the following detailed description and effects.
본 발명은 유효성분으로 해부석, 백반, 녹반, 노감석, 용뇌, 창이자 추출물, 고삼 추출물, 천초 추출물, 황백 추출물, 오배자 추출물, 황산겐타마이신, 디프로피온산베타메타손, 및 오소리 기름을 포함하는 피부외용 조성물을 제공한다.The present invention is an external skin composition comprising an anatomical stone, alum, green spots, sensitized stone, yongnae, changja extract, red ginseng extract, cheoncho extract, baekbaek extract, ginseng extract, gentamicin, dipropionate betamethasone, and badger oil To provide.
본 발명의 조성물 중 해부석(海孚石; pumex)은 화산에서 분출된 암석이 응고하여 이루어진 구멍이 많은 규산염 광물([SiO2]x)로서 필수 미네랄인 칼슘, 철, 아연, 구리, 니켈, 크롬, 코발트, 바나듐, 셀레늄 등을 함유하고 있으며, 피부에 혹이나 멍울이 지는 증상, 극심한 하복통을 치료하며 부스럼을 가라앉히는 효능이 있다고 알려져 있다.Anatomical stone (pumex) in the composition of the present invention is a porous silicate mineral ([SiO 2 ] x) formed by the solidification of rocks spewed from volcanoes, which are essential minerals calcium, iron, zinc, copper, nickel, It contains chromium, cobalt, vanadium, and selenium. It is known to cure swelling by treating lumps and bumps on the skin and extreme abdominal pain.
본 발명의 조성물 중 백반(白礬; Alumen)은 황산알루미늄과 리튬 이외의 알칼리금속·탈륨·암모늄 등 1가(價) 금속의 황산염이 만드는 복염(複鹽)으로 명반(明礬)이라고도 하고, 알루미늄 대신에 다른 3가의 금속이온이 치환된 것도 넓은 뜻에서 백반이라 하며, 지혈지사, 하혈, 살충해독, 수렴, 항균, 트리코모나스 질염, 액취증 개선 등에 효과가 있는 것으로 알려져 있다.Alumen in the composition of the present invention is a double salt formed by sulfates of monovalent metals such as alkali metals, thallium, and ammonium other than aluminum sulfate and lithium, and is also called alum. The substitution of other trivalent metal ions is also called alum in a broad sense, and is known to be effective for hemostasis, bleeding, insecticidal detoxification, convergence, antibacterial, trichomonas vaginitis, and liquor improvement.
본 발명의 조성물 중 녹반(綠礬: Melanterium)은 단사정계(單斜晶系)의 황산제이철을 함유한 황산 염류광물로 주요성분은 황산제일철(FeSO4·7H2O)이며, 거습, 살충, 보혈 등의 효능을 가진 것으로 알려져 있다.Melanterium of the composition of the present invention is a sulfate mineral containing monoclinic ferric sulfate, the main component is ferrous sulfate (FeSO 4 · 7H 2 O), moisture, insecticide, It is known to have an effect such as blood.
본 발명의 조성물 중 노감석(爐甘石; Calamina)은 동의보감에 명목, 수습, 염창, 지양, 퇴예, 해독 등의 효능을 가진 것으로 기재되어 있다.Calamina (조성물 石; Calamina) of the composition of the present invention has been described as having the efficacy of nominal, probationary, salty, lichen, baptismal, detoxification, etc. in synonym.
본 발명의 조성물 중 용뇌(龍腦; Borneol)는 동의보감에 소종, 청열지통 등의 효능을 가진 것으로 기재되어 있다.Borneol (조성물; Borneol) in the composition of the present invention has been described as having the efficacy of saengjong, blue heat pain, etc. in synonym.
본 발명의 조성물 중 창이자 추출물은 창이자의 용매 추출물로, 창이자(蒼耳子; Xanthii Fructus)는 산풍, 살충, 지통, 해독 등의 효능을 가진 것으로 동의보감에 기재되어 있다.Changzai extract in the composition of the present invention as a solvent extract of Changza, Xanthii Fructus is described in the synonym as having a potency, such as mountain breeze, insecticide, pain, detoxification.
본 발명의 조성물 중 고삼 추출물은 고삼의 용매 추출물로, 고삼(苦蔘; Sophorae Radix)은 동의보감에 거풍살충, 청열조습 등의 효능을 가진 것으로 기재되어 있다.The ginseng extract of the composition of the present invention is a solvent extract of the ginseng, and the ginseng (苦 蔘) (Sophorae Radix) has been described as having the effect of the insecticidal insects, chungpung insect, blue heat humidity.
본 발명의 조성물 중 천초 추출물은 천초의 용매 추출물로, 천초(川椒; Zanthoxhli Pericarpium)는 동의보감에 살충, 제습지통 등의 효능을 가진 것으로 기재되어 있다.Cheoncho extract in the composition of the present invention is a solvent extract of Cheoncho, Cheoncho (川椒; Zanthoxhli Pericarpium) has been described as having the efficacy of insecticide, dehumidification pain, etc. in synonym.
본 발명의 조성물 중 황백 추출물은 황백의 용매 추출물로, 황백(黃柏; Phellodendri Cortex)은 동의보감에 사화해독, 청열조습 등의 효능을 가진 것으로 기재되어 있다.The sulfur extract of the composition of the present invention is a solvent extract of sulfur white, sulfur white (黃柏; Phellodendri Cortex) has been described as having the effects of detoxification, blue heat humidity, etc. in synonym.
본 발명의 조성물 중 오배자 추출물은 오배자의 용매 추출물로, 오배자(五倍子; Galla Rhois)는 동의보감에 지혈, 해독 등의 효능을 가진 것으로 기재되어 있다.The gall bladder extract of the composition of the present invention is a gall bladder solvent extract, the gall bladder (五倍子; Galla Rhois) has been described as having the effect of hemostasis, detoxification, etc. in synonym.
본 발명의 조성물 중 황산겐타마이신(Gentamicin Sulfate)은 항세균활성을 가진 아미노글리코사이드계 화합물의 황산염으로, 전염성농가진 등의 1차 피부감염증과 화농성세균에 의하여 2차 감염된 지루피부염, 진균 또는 바이러스의 감염에 의한 중복 감염 등의 2차 피부감염증의 치료에 사용되고 있다.Gentamicin sulfate in the composition of the present invention is a sulfate of an aminoglycoside-based compound having antibacterial activity, and is used to treat seborrheic dermatitis, fungus or virus secondaryly infected with primary skin infections such as infectious impetigo and purulent bacteria. It is used for the treatment of secondary skin infections such as duplicate infection caused by infection.
본 발명의 조성물 중 디프로피온산베타메타손(Betamethasone Dipropionate)는 소염성 코르티코스테로이드로 화학식 C28H37FO7의 화합물이며, 건선, 지루성 피부염, 과민성 피부염, 접촉성 피부염, 습진 등의 치료 효과를 갖고 있는 것으로 알려져 있다. Betamethasone Dipropionate in the composition of the present invention is an anti-inflammatory corticosteroid, a compound of formula C 28 H 37 FO 7 , and has a therapeutic effect such as psoriasis, seborrheic dermatitis, irritable dermatitis, contact dermatitis, eczema, etc. Known.
본 발명의 조성물 중 오소리 기름(Melis Sebum)은 윤조, 소종해독 등의 효능을 가진 것으로 알려져 있으며, 본 발명의 조성물에 있어 피부보호 작용 외에 기제의 역할을 함께하며, 피부에 침투가능하다.Badger oil (Melis Sebum) of the composition of the present invention is known to have the effect of lubrication, swelling detoxification, etc., in addition to the skin protective action in the composition of the present invention acts as a base and can penetrate the skin.
상기 황산겐타마이신, 디프로피온산베타메타손, 및 오소리 기름은 시판되는 것을 구입하거나 제조한 것일 수 있다.The gentamicin sulfate, dipropionate betamethasone, and badger oil may be purchased or manufactured from commercially available products.
상기 해부석, 백반, 녹반, 노감석, 및 용뇌는 분쇄하여 분말상으로 사용할 수 있으며, 바람직하게 분말의 입경은 300 ~ 500 메쉬(mesh)로 한다. 즉, 망목 300메쉬 체를 통과하고 500메쉬 체를 통과하지 않는 분말을 사용할 수 있다.The dissected stones, alum, green spots, sensitized stones, and chalcedony can be pulverized and used in powder form. Preferably, the particle size of the powder is 300 to 500 mesh. That is, it is possible to use a powder that passes through the mesh 300 mesh sieve and does not pass through the 500 mesh sieve.
상기 분말 입경이 500메쉬 체를 통과할 정도로 미세한 것은 피부에 흡수되거나 모공 등을 막을 염려가 있고, 300메쉬 체를 통과하지 못할 정도로 큰 것은 도포감이 좋지 않을 염려가 있다.The fine particles having a particle diameter of 500 mesh sieve may be absorbed by the skin or may block pores, and the coating particles may not have good coating feeling.
상기 추출물은 물 또는 유기용매, 또는 이들의 혼합용매로 추출한 것을 사용할 수 있다. 상기 유기용매는 통상 사용할 수 있는 모든 용매가 가능하며, 바람직하게는 물, C1-4알콜(예를 들어 메탄올, 또는 에탄올 등) 등의 극성용매 또는 이들의 혼합물을 사용할 수 있다.The extract may be extracted with water or an organic solvent, or a mixed solvent thereof. The organic solvent may be any solvent that can be used in general, preferably a polar solvent such as water, C1-4 alcohol (for example, methanol, ethanol and the like) or a mixture thereof.
상기 추출은 열탕추출 등 통상의 방법으로 행할 수 있으며, 추출물을 동결건조하여 사용할 수 있다. 또한 상기 추출물은 통상의 분획법 또는 크로마토그라피에 의해 보다 정제하여 사용할 수 있다.The extraction can be carried out by conventional methods such as hot water extraction, it can be used by lyophilizing the extract. In addition, the extract can be used more purified by conventional fractionation or chromatography.
본 발명의 조성물은 피부질환에 효과를 나타내며, 아토피성 피부염, 무좀, 습진 등에 유효한 효과를 나타낸다.The composition of the present invention has an effect on skin diseases, and has an effective effect on atopic dermatitis, athlete's foot, eczema and the like.
따라서, 본 발명은 상기 조성물의 아토피성 피부염 개선용도 및 상기 조성물을 대상자에게 투여하는 단계를 포함하는 아토피성 피부염 개선방법을 제공한다.Accordingly, the present invention provides a method for improving atopic dermatitis and administering the composition to a subject.
본 발명의 조성물은 상기 해부석 100중량부에 대하여 상기 백반 50 ~ 200 중량부, 상기 녹반 50 ~ 200 중량부, 상기 노감석 50 ~ 200 중량부, 상기 용뇌 50 ~ 200 중량부, 상기 창이자 추출물 50 ~ 200 중량부, 상기 고삼 추출물 50 ~ 200 중량부, 상기 천초 추출물 25 ~ 200 중량부, 상기 황백 추출물 50 ~ 200 중량부, 상기 오배자 추출물 50 ~ 200 중량부, 상기 황산겐타마이신 0.1 ~ 1 중량부, 상기 디프로피온산베타메타손 5 ~ 20 중량부, 및 상기 오소리 기름 4000 ~ 16000중량부를 가질 수 있다.The composition of the present invention is 50 to 200 parts by weight of the alum, 50 to 200 parts by weight, 50 to 200 parts by weight, 50 to 200 parts by weight of the sensitized stone, 50 to 200 parts by weight of the chalcedony extract 50 ~ 200 parts by weight, the ginseng extract 50 ~ 200 parts by weight, the Cheoncho extract 25 ~ 200 parts by weight, the baekbaek extract 50 ~ 200 parts by weight, the gall bladder extract 50 ~ 200 parts by weight, the gentamicin sulfate 0.1 ~ 1 parts by weight 5 to 20 parts by weight of the dipropionate betamethasone, and 4000 to 16000 parts by weight of the badger oil.
본 발명의 조성물 중 창이자 추출물, 고삼 추출물, 천초추출물, 황백추출물, 및 오배자추출물은 창이자, 고삼, 천초, 황백, 및 오배자를 혼합하여 추출한 혼합추출물일 수 있으며, 상기 혼합추출물을 포함하는 조성물 중 해부석 100중량부에 대하여 상기 백반 50 ~ 200 중량부, 상기 녹반 50 ~ 200 중량부, 상기 노감석 50 ~ 200 중량부, 상기 용뇌 50 ~ 200 중량부, 상기 혼합추출물 225 ~ 1000 중량부, 상기 황산겐타마이신 0.1 ~ 1 중량부, 상기 디프로피온산베타메타손 5 ~ 20 중량부, 및 상기 오소리 기름 4000 ~ 16000중량부일 수 있다.Changzai extract, Gosam extract, cheoncho extract, yellowish white extract, and quinine extract in the composition of the present invention may be a mixed extract extracted by mixing Changja, red ginseng, cheoncho, baekbaek, and quintet, dissecting the composition comprising the mixed extract 50 to 200 parts by weight of the alum, 50 to 200 parts by weight of the green spot, 50 to 200 parts by weight of the sensitized stone, 50 to 200 parts by weight of the bracts, 225 to 1000 parts by weight of the mixed extract, the sulfuric acid It may be 0.1 to 1 parts by weight of gentamicin, 5 to 20 parts by weight of the betamethasone dipropionate, and 4000 to 16000 parts by weight of the badger oil.
본 발명의 조성물은 상술한 유효성분 이외에, 당업계에 공지된 추가의 아토피 피부염 개선 작용을 나타내는 물질을 추가로 포함할 수 있다.The composition of the present invention, in addition to the above-mentioned effective ingredient, may further include a substance exhibiting additional atopic dermatitis improving action known in the art.
본 발명의 조성물은 다양한 방식 또는 형태로 인체에 적용될 수 있으나, 바람직하게는 피부에 국소적으로 도포되어 적용가능하며, 피부외용 제형을 갖는다. 즉, 연고제, 겔제, 크림제, 리니멘트제, 로션제, 액제, 또는 에어로졸제 등이다.The composition of the present invention may be applied to the human body in various ways or forms, but is preferably applied topically to the skin, and has an external skin formulation. That is, ointments, gels, creams, linings, lotions, liquids, or aerosols.
본 발명의 조성물은 약학 조성물일 수 있다.The composition of the present invention may be a pharmaceutical composition.
상기 약학 조성물은 약학적으로 허용되는 담체를 포함한다.The pharmaceutical composition comprises a pharmaceutically acceptable carrier.
약학적으로 허용되는 담체는 락토스, 덱스트로스, 수크로스, 전분, 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로즈 용액, 말토덱스트린 용액, 글리세롤, 에탄올 등 중 하나 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제, 안정화제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 용매, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제를 부가적으로 첨가할 수 있다. 더 나아가 당 분야의 적절한 방법으로 또는 Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.Pharmaceutically acceptable carriers may be used by mixing one or more of lactose, dextrose, sucrose, starch, saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and the like. If desired, other conventional additives such as antioxidants, buffers, bacteriostatics, stabilizers, etc. may be added. Diluents, dispersants, surfactants, solvents, disintegrants, sweeteners, binders, coatings, swelling agents, lubricants, lubricants or flavoring agents may additionally be added. Furthermore, it may be preferably formulated according to each disease or component by any suitable method in the art or using methods disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.
연고제로 제제화할 경우 본 발명의 조성물 외에 연고기제, 기타 첨가물 등을 적절하게 배합하여 제조할 수 있다. 연고기제, 기타 첨가물은 고급지방산 또는 그 에스테르류, 납류, 계면활성제, 고급알코올, 실리콘유, 탄화수소류, 물, 보습제, 감염방지제 등에서 적당히 선택하여 사용할 수 있다.When formulated into an ointment, in addition to the composition of the present invention can be prepared by appropriately mixing the ointment, other additives and the like. The ointment and other additives may be appropriately selected from higher fatty acids or esters thereof, lead, surfactants, higher alcohols, silicone oils, hydrocarbons, water, humectants, and anti-infective agents.
본 발명의 약학 조성물은 비경구 투여, 바람직하게는 도포에 의한 국부투여(topical application)에 의한다.The pharmaceutical composition of the present invention is by parenteral administration, preferably topical application by application.
본 발명의 약학 조성물은 피부외용 제형 즉, 파우더, 젤, 연고, 크림, 액체 또는 에어로졸 제형으로 제조가능하다.The pharmaceutical composition of the present invention may be prepared in an external dermal formulation, i.e. powder, gel, ointment, cream, liquid or aerosol formulation.
본 발명에 따른 약학 조성물에 있어서 활성성분의 투여량은 체중 60kg 성인기준으로 0.1mg/kg ~ 1000mg/kg의 범위 내에서 조절할 수 있다. 다만, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다.In the pharmaceutical composition according to the present invention, the dosage of the active ingredient may be adjusted within the range of 0.1 mg / kg to 1000 mg / kg based on an adult weight of 60 kg. However, the optimum dosage to be administered can be easily determined by those skilled in the art, and the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, general health of the patient It may be adjusted according to various factors including the condition, sex and diet, time of administration, and the rate of secretion of the composition, the duration of treatment, and the drugs used simultaneously.
또한, 본 발명의 조성물은 화장료 조성물일 수 있다.In addition, the composition of the present invention may be a cosmetic composition.
본 발명의 화장료 조성물에는 화장료 조성물에 통상적으로 포함되는 성분이 포함될 수 있으며, 예를 들어 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 담체 등을 포함할 수 있다.The cosmetic composition of the present invention may include components conventionally included in the cosmetic composition, and may include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, carriers, and the like.
상기 화장료 조성물은 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 크린징, 또는 스프레이 등으로 제조될 수 있다.The cosmetic composition may be prepared in any of the formulations conventionally prepared, and may be prepared, for example, as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, cleansing, spray, or the like.
또한, 본 발명은 (a) 해부석, 백반, 녹반, 노감석, 및 용뇌를 분쇄하여 분쇄물을 얻는 단계; (b) 창이자, 고삼, 천초, 황백, 및 오배자를 물에 침지한 후 가열하여 열수추출물을 얻는 단계; (c) 황산 겐타마이신, 디프로피온산베타메타손, 및 오소리 기름을 혼합하여 혼합물을 얻는 단계; 및 (d) 상기 (a)단계의 분쇄물, 상기 (b)단계의 열수추출물, 및 상기 (c)단계의 혼합물을 혼합하는 단계를 포함하는 피부외용 조성물 제조방법을 제공한다.In addition, the present invention comprises the steps of (a) pulverizing anatomical stone, alum, green spots, sensitized stone, and chalcedony; (b) distilling Changja, red ginseng, cheoncho, baekbaek, and gallengja in water and then heating to obtain a hot water extract; (c) mixing gentamicin sulfate, betamethasone dipropionate, and badger oil to obtain a mixture; And (d) mixing the ground powder of step (a), the hot water extract of step (b), and the mixture of step (c).
구체적으로 본 발명의 제조방법은 다음과 같으며, 제조방법에 사용되는 해부석, 백반, 녹반, 노감석, 용뇌, 창이자, 고삼, 천초, 황백, 오배자, 황산 겐타마이신, 디프로피온산베타메타손, 및 오소리 기름에 관한 내용은 상기 본 발명의 조성물에서와 동일하다.Specifically, the production method of the present invention is as follows, anatomical stone, alum, green spot, sensitized stone, chalcedony, changja, red ginseng, cheoncho, baekbaek, galleng, gentamicin sulfate, dipropionate betamethasone, and badger The content of oil is the same as in the composition of the present invention.
상기 (a)단계에서 해부석 100중량부에 대하여 백반 50 ~ 200 중량부, 녹반 50 ~ 200 중량부, 노감석 50 ~ 200 중량부, 용뇌 50 ~ 200 중량부를 혼합하여 분쇄기로 분쇄한 후 체과하여 300 ~ 500 메쉬의 입경을 갖는 분쇄물을 제조할 수 있다.50 to 200 parts by weight of alum, 50 to 200 parts by weight of alum, 50 to 200 parts by weight of unreacted stone, and 50 to 200 parts by weight of pulverum are mixed and pulverized with a grinder in step (a). A pulverized product having a particle size of 300 to 500 mesh can be produced.
상기 (b)단계의 창이자는 도꼬마리(Xanthium strumarium L.)의 성숙한 과실을 120 ~ 170℃ 온도에서 10 ~ 40분간 가열하여 가시를 태워 제거한 것을 준비하고, 고삼은 고삼(Sophora flavescens AIT.)의 뿌리를 수세한 후, 쌀뜨물에 8 ~ 12 시간 침지한 후, 10~30 ℃온도로 20~40일간 건조하여 준비할 수 있다.The window of step (b) was prepared by heating the mature fruit of Xanthium strumarium L. at 120 to 170 ° C. for 10 to 40 minutes to remove thorns, and the root of the ginseng (Sophora flavescens AIT.) After washing with water, it is immersed in rice water for 8 to 12 hours, it can be prepared by drying for 20 to 40 days at 10-30 ℃ temperature.
상기 (b)단계에서 열수추출물은 창이자, 고삼, 천초, 황백, 및 오배자를 중량비로 50~200 : 50~200 : 25~200 : 50~200 : 50~200로 하여 혼합한 후, 혼합물에 대하여 부피비로 3~7배인 정제수에 혼합물을 침지한 후 90~120 ℃온도로 4~6 시간 가열한 후, 고형분을 걸러내고 다시 90~120℃온도로 4~6시간 가열, 농축하여 제조할 수 있다.The hot water extract in the step (b) is Changja, Gosam, Cheoncho, Yellow and White, and five ginseng in a weight ratio of 50 to 200: 50 to 200: 25 to 200: 50 to 200: 50 to 200, and then mixed with respect to the mixture After immersing the mixture in purified water having a volume ratio of 3-7 times, the mixture is heated at 90-120 ° C. for 4-6 hours, the solids are filtered off, and heated and concentrated at 90-120 ° C. for 4-6 hours. .
상기 (c)단계에서 오소리 기름은 오소리의 지방을 500 ~ 800 ℃온도로 1.5 ~ 4시간 가열하여 제조할 수 있으며, 상기 (c)단계의 혼합물은 황산겐타마이신, 디프로피온산베타메타손, 및 오소리기름을 중량비로 0.1 ~ 1 : 5 ~ 20 : 4000 ~ 16000으로 하여 혼합된 것일 수 있다. 오소리기름은 조성물의 총량을 맞추기 위해 (d)단계에서 추가될 수 있다.Badger oil in step (c) may be prepared by heating the fat of badger at a temperature of 500 ~ 800 ℃ 1.5 ~ 4 hours, the mixture of step (c) is a gentamicin sulfate, dipropionate betamethasone, and badger oil It may be mixed in a weight ratio of 0.1 to 1: 5 to 20: 4000 to 16000. Badger oil may be added in step (d) to match the total amount of the composition.
상기 (d)단계에서 혼합되는 열수추출물은 (a)단계의 해부석 100중량부에 대하여 225 ~ 1000중량부일 수 있다.The hot water extract mixed in step (d) may be 225 to 1000 parts by weight based on 100 parts by weight of the anatomical stone of step (a).
상기 (c)단계 및 (d)단계의 혼합은 공지의 믹서 등을 사용하여 혼합할 수 있고, 상기 (d)단계를 거친 후 제품으로 포장하는 단계를 추가로 거쳐 완제품을 제조할 수 있다.The mixing of the steps (c) and (d) may be mixed using a known mixer, etc., and after the step (d), the finished product may be manufactured by further packaging the product.
본 발명의 조성물은 아토피성 피부염, 무좀, 습진 등의 피부질환에 효과적이며, 부작용과 재발가능성이 낮은 장점을 갖는다. 또한, 본 발명의 제조방법에 의해 본 발명의 조성물을 효과적으로 제조할 수 있다.The composition of the present invention is effective in skin diseases such as atopic dermatitis, athlete's foot, eczema, and has the advantage of low side effects and low recurrence. Moreover, the composition of this invention can be manufactured effectively by the manufacturing method of this invention.
도 1은 실시예 1의 조성물 사용 전의 피부상태를 촬영한 사진이다.1 is a photograph of the skin condition before using the composition of Example 1.
도 2는 5개월간 실시예 1의 조성물을 사용한 후의 피부상태를 촬영한 사진이다.Figure 2 is a photograph of the skin condition after using the composition of Example 1 for 5 months.
본 발명의 이해를 돕기 위하여 실시예를 제시한다. 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Examples are provided to help understand the present invention. The following examples are merely provided to more easily understand the present invention, but the contents of the present invention are not limited by the examples.
<실시예 1> 피부외용 조성물 제조Example 1 Preparation of External Skin Composition
(1-1) 해부석(대광건재, 춘천, 대한민국) 6.4g, 백반(대광건재, 춘천, 대한민국) 6.4g, 녹반(대광건재, 춘천, 대한민국) 6.4g, 노감석(대광건재, 춘천, 대한민국) 6.4g, 및 용뇌(대광건재, 춘천, 대한민국) 6.4g을 분쇄기로 분쇄하고 체과하여 300 ~ 500메쉬의 분말을 제조하였다.(1-1) Anatomy Stone (Daegwang Construction Material, Chuncheon, Korea) 6.4g, Baekban (Daegwang Construction Material, Chuncheon, Korea) 6.4g, Nokban (Daegwang Construction Material, Chuncheon, Korea) 6.4g Korea) 6.4g, and yonggyong (Daegwang building materials, Chuncheon, Korea) 6.4g was pulverized and pulverized to prepare a powder of 300 ~ 500 mesh.
(1-2) 창이자(대광건재, 춘천, 대한민국) 10g, 고삼(대광건재, 춘천, 대한민국) 10g, 천초(대광건재, 춘천, 대한민국) 5g, 황백(대광건재, 춘천, 대한민국) 10g, 및 오배자(대광건재, 춘천, 대한민국) 10g에 약제 총부피의 3배인 정제수를 붓고, 100 ℃로 5시간 가열한 후, 액상을 여과하고 여과액을 다시 100℃로 가열하여 25g이 될 때까지 가열하여 혼합추출물을 제조하였다.(1-2) Changza (Daegwang Building, Chuncheon, Korea) 10g, Gosam (Daegwang Building, Chuncheon, Korea) 10g, Cheoncho (Daegwang Building, Chuncheon, Korea) 5g, Hwangbaek (Daegwang Building, Chuncheon, Korea) 10g, and Pour purified water that is three times the total volume of the drug into 10g of Ohbaeja (Daegwang building materials, Chuncheon, Korea), heat it to 100 ° C for 5 hours, filter the liquid and heat the filtrate to 100 ° C until it reaches 25g. A mixed extract was prepared.
상기 창이자는 도꼬마리를 팬에서 170 ℃로 25분간 가열하여 가시를 태워 제거한 것을 사용하였다.The window was used to remove the burned thorns by heating the dog nose to 170 ℃ for 25 minutes in a pan.
상기 고삼은 고삼의 뿌리를 수세하고, 쌀뜨물에 10 시간 침지한 후, 25~28℃로 30일간 건조한 것을 사용하였다.The ginseng was washed with the root of the ginseng, immersed in rice water for 10 hours, and then used to dry for 30 days at 25 ~ 28 ℃.
(1-3) 황산겐타마이신(한국약업조합, 서울, 대한민국) 25mg, 디프로피온산베타메타손(한국약업조합, 서울, 대한민국) 600mg, 및 오소리 기름을 혼합하여 혼합물을 제조하였다. 오소리 기름은 강원도에서 포획한 야생 오소리의 지방 8.5kg을 채취한 후 600℃에서 2시간 가열하여 얻어진 기름(1.8kg)을 사용하였고, 오소리 기름은 최종 조성물 양이 총 500g이 되도록 하는 잔량을 사용하였다.(1-3) A mixture was prepared by mixing 25 mg of gentamicin sulfate (Korea Pharmaceutical Association, Seoul, Korea), 600 mg of dipropionate betamethasone (Korea Pharmaceutical Association, Seoul, South Korea), and badger oil. Badger oil was used as the oil (1.8kg) obtained by heating 8.5kg fat of wild badger captured in Gangwon-do and heating at 600 ℃ for 2 hours, and badger oil was used to make the final composition total 500g. .
(1-4) 상기 (1-1)의 분말, 및 (1-2)의 추출물을 (1-3)의 혼합물과 혼합하여 피부외용 조성물을 제조하였다. (1-4) The powder of (1-1) and the extract of (1-2) were mixed with the mixture of (1-3) to prepare an external composition for skin.
<비교예 1> 황산겐타마이신, 디프로피온산베타메타손, 및 오소리기름 함유 조성물 제조Comparative Example 1 Preparation of Gentamicin Sulfate, Betamethasone Dipropionate, and Badger Oil-Containing Composition
실시예 (1-3)의 혼합물 제조방법과 동일하게, 비교예 1의 조성물을 제조하였다.In the same manner as in the preparation of the mixture in Example (1-3), the composition of Comparative Example 1 was prepared.
<비교예 2> 창이자, 고삼, 천초, 황백, 및 오배자 추출물과 오소리기름 함유 조성물 제조<Comparative Example 2> Preparation of Changjaza, Gosam, Cheoncho, Yellowish White, and Ginseng Extract and Badger Oil-Containing Composition
실시예 (1-2)의 추출물 제조방법과 동일하게 제조한 추출물과 실시예 (1-3)의 오소리기름과 동일하게 제조한 오소리기름(최종조성물이 총 500g이 되도록 하는 잔량)을 혼합하여 비교예 2의 조성물을 제조하였다.Comparison by mixing the extract prepared in the same manner as the extract preparation method of Example (1-2) and the badger oil (the remaining amount so that the final composition is a total of 500g) prepared in the same manner as the badger oil of Example (1-3) The composition of Example 2 was prepared.
<비교예 3> 해부석, 백반, 녹반, 노감석, 용뇌, 및 오소리기름 함유 조성물 제조Comparative Example 3 Preparation of Anatomic Stone, Aluminous Table, Green Plate, Nogam Stone, Dragon Head, and Badger Oil-Containing Composition
실시예 (1-1)의 분쇄물 제조방법과 동일하게 제조한 분쇄물과 실시예 (1-3)의 오소리기름과 동일하게 제조한 오소리기름(최종조성물이 총 500g이 되도록 하는 잔량)을 혼합하여 비교예 3의 조성물을 제조하였다.Mixing the ground powder prepared in the same manner as in the milled product preparation of Example (1-1) and the badger oil (the remaining amount of the final composition totaling 500 g) prepared in the same manner as the badger oil of Example (1-3) To prepare a composition of Comparative Example 3.
<비교예 4> 창이자, 고삼, 천초, 황백, 및 오배자 추출물과 해부석, 백반, 녹반, 노감석, 및 용뇌와 오소리기름 함유 조성물 제조Comparative Example 4 Preparation of Changjaza, Red Ginseng, Cheoncho, Yellowish White, and Ginseng Extract, and Anatomical Stones, Alum, Green Spots, Nogamstones, and Brain and Badger Oil-Containing Compositions
황산겐타마이신과 디프로피온산베타메타손을 사용하지 않은 것을 제외하고, 실시예 1과 동일하게 비교예 4의 조성물을 제조하였다.A composition of Comparative Example 4 was prepared in the same manner as in Example 1, except that gentamicin sulfate and betamethasone dipropionate were not used.
<비교예 5> 오소리기름의 준비Comparative Example 5 Preparation of Badger Oil
실시예 (1-3)에서 사용한 오소리기름과 동일하게 제조한 오소리기름을 500g 준비하였다.500 g of badger oil prepared in the same manner as in Example (1-3) were prepared.
<실험예 1> 아토피성 피부염 개선 효과 확인 실험 1Experimental Example 1 Atopic Dermatitis Improvement Effect Confirmation Experiment 1
아토피성 피부염을 앓고 있는 환자 100명(5 ~ 50세 남녀)을 대상으로 실시예 1의 조성물, 비교예 1 내지 5의 조성물을 사용하여 4주간 아토피성 피부염 개선 효과 확인 실험을 실시하였다. 실시예 1의 조성물을 50명에게 사용하도록 하였고, 비교예 1 내지 5의 조성물 각 10명에게 사용하도록 하였으며, 1일 3회 환부에 얇게 펴바르도록 하였다. 시험도중 해당 증상이 없어진 경우는 더 이상 사용하지 않도록 하였다.100 patients (5-50 years old male and female) suffering from atopic dermatitis were tested for atopic dermatitis improvement effect for 4 weeks using the composition of Example 1 and the compositions of Comparative Examples 1-5. The composition of Example 1 was to be used for 50 people, each of the compositions of Comparative Examples 1 to 5 was to be used for 10 people, three times a day to spread thinly on the affected area. If the symptom disappeared during the test, it was no longer used.
효과는 각각의 조성물 사용 전과 후에 아토피 개선효과 평가법(Local SCORAD)을 사용하여 평가하였다. The effect was assessed using the Atopic Improvement Test (Local SCORAD) before and after using each composition.
임상평가항목은 총 6개로 1) 홍반(Erythema), 2) 부종/구진(Edema/Papulation), 3) 삼출/가피(Oozing/Crust), 4) 표피박리(Excoriation), 5) 태선화(Lichenification), 6) 건조(Dryness)이었으며, 각각의 항목에 대하여 정도에 따라 4단계(0=해당 증상 없음, 1=해당 증상 약하게 있음, 2=해당 증상 중간 정도 있음, 3=해당 증상 심함)로 평가한 후 6개의 항목의 값을 모두 합하여 평가하였다.A total of 6 clinical evaluation items were 1) Erythema, 2) Edema / Papulation, 3) Oozing / Crust, 4) Excoriation, 5) Lichenification , 6) Dryness, and each item was evaluated in four stages (0 = no symptom, 1 = negative symptom, 2 = medium symptom, 3 = severe symptom) depending on the degree. Then, the values of all six items were summed and evaluated.
개인별 개선율은 하기 수학식 1로 계산하였으며, 개선율 평균은 개인별 개선율의 총합을 대상자 수로 나누어 구하였다(수학식 2). 그 결과를 표 1에 나타내었다.The improvement rate for each individual was calculated by Equation 1 below, and the average improvement rate was obtained by dividing the total improvement rate for each individual by the number of subjects (Equation 2). The results are shown in Table 1.
[수학식 1][Equation 1]
개선율(%)={(사용전 6개 항목 점수 합계 - 사용후 6개 항목 점수 합계)/사용전 6개 항목 점수 합계} × 100(%)% Improvement = {(Sum of 6 items before use-Sum of 6 items after use) / Sum of 6 items before use} × 100 (%)
[수학식 2][Equation 2]
개선율 평균(%/인)=개선율 총합(%)÷대상자 수(인)Average improvement rate (% / person) = total improvement rate (%) ÷ number of people (person)
표 1
개선율 총합(%) 대상자 수(인) 개선율 평균(%/인)
실시예 1 3416.35 50 68.33
비교예 1 161.12 10 16.11
비교예 2 183.34 10 18.33
비교예 3 166.68 10 16.67
비교예 4 305.53 10 30.55
비교예 5 122.22 10 12.22
Table 1
% Improvement Audience Count % Average improvement
Example 1 3416.35 50 68.33
Comparative Example 1 161.12 10 16.11
Comparative Example 2 183.34 10 18.33
Comparative Example 3 166.68 10 16.67
Comparative Example 4 305.53 10 30.55
Comparative Example 5 122.22 10 12.22
표 1의 결과로부터 실시예 1의 조성물은 비교예 1 내지 5의 경우에 비해 아토피성 피부염의 개선 효과가 우수함을 알 수 있다.From the results of Table 1, it can be seen that the composition of Example 1 has an excellent effect of improving atopic dermatitis compared to the cases of Comparative Examples 1 to 5.
실시예 1의 조성물을 사용한 평가대상자 중 무좀을 앓고 있었던 17명과 습진을 앓고 있었던 20명의 경우는 무좀부위와 습진부위에도 사용하여, 증세가 개선되었음을 보고하였다.Among the subjects using the composition of Example 1, 17 patients with athlete's foot and 20 patients with eczema were used for athlete's foot and eczema, and the symptoms were reported to be improved.
또한, 평가 대상자 중 실시예 1의 조성물을 사용한 50명은 완치될 때까지 추가로 4 ~ 5개월간 동일한 방식으로 실시예 1의 조성물을 사용하였으며, 완치 후 6개월 경과시 아토피성 피부염 재발과 부작용 여부에 대하여 조사하였다. 그 결과 아토피성 피부염이 재발한 경우나 부작용이 나타난 경우는 조사되지 않았다.In addition, 50 of the subjects using the composition of Example 1 was used for the composition of Example 1 in the same manner for an additional 4 to 5 months until complete cured, 6 months after cure if atopic dermatitis recurrence and side effects Was investigated. As a result, a case of recurrence or side effects of atopic dermatitis was not investigated.
실시예 1의 조성물을 5개월간 사용한 평가 대상자 중 1인에 대하여 사용전과 5개월 경과 후 피부상태를 촬영하였고, 그 결과를 도 1과 도 2에 나타내었다. 도 1은 사용전 피부상태를 촬영한 것이고, 도 2는 5개월 사용한 후의 피부상태를 촬영한 것이다. 그 결과 실시예 1의 조성물 사용에 의해 아토피성 피부염이 개선되는 것을 확인할 수 있다.One of the subjects who used the composition of Example 1 for 5 months was photographed before and after 5 months of use, and the results are shown in FIGS. 1 and 2. 1 is a photograph of the skin condition before use, Figure 2 is a photograph of the skin condition after 5 months of use. As a result, it can be confirmed that atopic dermatitis is improved by using the composition of Example 1.
이와 같은 결과로부터 본 발명의 조성물은 아토피성 피부염 등에 효과적이며, 재발이나 부작용의 문제도 없는 것을 확인하였다.From these results, it was confirmed that the composition of the present invention is effective in atopic dermatitis and the like, and has no problem of recurrence or side effects.

Claims (12)

  1. 유효성분으로 해부석, 백반, 녹반, 노감석, 용뇌, 창이자 추출물, 고삼 추출물, 천초 추출물, 황백 추출물, 오배자 추출물, 황산겐타마이신, 디프로피온산베타메타손, 및 오소리 기름을 포함하는 피부외용 조성물.Skin external composition comprising anatomical stone, alum, green spot, sensitized stone, cerebrum, changja extract, red ginseng extract, cheoncho extract, baekbaek extract, gallant extract, gentamicin sulfate, dimethionate betamethasone, and badger oil.
  2. 제1항에 있어서, 상기 조성물은 아토피성 피부염 개선용인 조성물.According to claim 1, wherein the composition is a composition for improving atopic dermatitis.
  3. 제1항에 있어서, 상기 해부석, 상기 백반, 상기 녹반, 상기 노감석, 및 상기 용뇌는 입경 300 ~ 500메쉬인 피부외용 조성물.The skin external composition of claim 1, wherein the anatomical stone, the alum, the green spot, the sensitized stone, and the head of the brain have a particle size of 300 to 500 mesh.
  4. 제1항에 있어서, 상기 해부석 100중량부에 대하여 상기 백반 50 ~ 200 중량부, 상기 녹반 50 ~ 200 중량부, 상기 노감석 50 ~ 200 중량부, 상기 용뇌 50 ~ 200 중량부, 상기 창이자 추출물 50 ~ 200 중량부, 상기 고삼 추출물 50 ~ 200 중량부, 상기 천초 추출물 25 ~ 200 중량부, 상기 황백 추출물 50 ~ 200 중량부, 상기 오배자 추출물 50 ~ 200 중량부, 상기 황산겐타마이신 0.1 ~ 1 중량부, 상기 디프로피온산베타메타손 5 ~ 20 중량부, 및 상기 오소리 기름 4000 ~ 16000중량부인 조성물. According to claim 1, 50 to 200 parts by weight of the alum, 50 to 200 parts by weight, 50 to 200 parts by weight, 50 to 200 parts by weight of the sensitized stone, 50 to 200 parts by weight of the bractite, the Changza extract 50 to 200 parts by weight, 50 to 200 parts by weight of the ginseng extract, 25 to 200 parts by weight of the cheoncho extract, 50 to 200 parts by weight of the baekbaek extract, 50 to 200 parts by weight of the gall bladder extract, 0.1 to 1 weight of the gentamicin sulfate Part, 5 to 20 parts by weight of the betamethasone dipropionate, and 4000 to 16000 parts by weight of the badger oil.
  5. 제1항에 있어서, 상기 창이자 추출물, 상기 고삼 추출물, 상기 천초추출물, 상기 황백추출물, 및 상기 오배자추출물은 창이자, 고삼, 천초, 황백, 및 오배자를 혼합하여 열수추출한 열수추출물인 조성물.The composition of claim 1, wherein the Changjaja extract, the Ginseng extract, the Cheoncho extract, the Yellow White extract, and the Goongja extract are hot water extracts obtained by mixing Changja, Gosam, Cheoncho, Yellow and White, and the Gobae.
  6. 제5항에 있어서, 상기 해부석 100중량부에 대하여 상기 백반 50 ~ 200 중량부, 상기 녹반 50 ~ 200 중량부, 상기 노감석 50 ~ 200 중량부, 상기 용뇌 50 ~ 200 중량부, 상기 열수추출물 225 ~ 1000 중량부, 상기 황산겐타마이신 0.1 ~ 1 중량부, 상기 디프로피온산베타메타손 5 ~ 20 중량부, 및 상기 오소리 기름 4000 ~ 16000중량부인 조성물.According to claim 5, 50 to 200 parts by weight of the alum, 50 to 200 parts by weight, 50 to 200 parts by weight, 50 to 200 parts by weight of the sensitized stone, 50 to 200 parts by weight of the brain powder, the hot water extract 225 to 1000 parts by weight, 0.1 to 1 parts by weight of the gentamicin sulfate, 5 to 20 parts by weight of the betamethasone dipropionate, and 4000 to 16000 parts by weight of the badger oil.
  7. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 조성물은 약학 조성물인 조성물.The composition of claim 1, wherein said composition is a pharmaceutical composition.
  8. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 조성물은 화장료 조성물인 조성물.The composition of claim 1, wherein the composition is a cosmetic composition.
  9. (a) 해부석, 백반, 녹반, 노감석, 및 용뇌를 분쇄하여 분쇄물을 얻는 단계;(a) pulverizing anatomical stone, alum, green spots, sensitized rocks, and brains to obtain a pulverized product;
    (b) 창이자, 고삼, 천초, 황백, 및 오배자를 물에 침지한 후 가열하여 열수추출물을 얻는 단계;(b) distilling Changja, red ginseng, cheoncho, baekbaek, and gallengja in water and then heating to obtain a hot water extract;
    (c) 황산 겐타마이신, 디프로피온산베타메타손, 및 오소리 기름을 혼합하여 혼합물을 얻는 단계; 및(c) mixing gentamicin sulfate, betamethasone dipropionate, and badger oil to obtain a mixture; And
    (d) 상기 (a)단계의 분쇄물, 상기 (b)단계의 열수추출물, 및 상기 (c)단계의 혼합물을 혼합하는 단계를 포함하는 피부외용 조성물 제조방법.(d) a method for preparing an external composition for skin comprising the step of mixing the pulverized product of step (a), the hot water extract of step (b), and the mixture of step (c).
  10. 제9항에 있어서, 상기 (a)단계의 분쇄는 분쇄물의 입경이 300 ~ 500 메쉬가 되도록 분쇄하는 것인 제조방법.10. The method according to claim 9, wherein the pulverization of step (a) is pulverized so that the particle size of the pulverized product is 300 to 500 mesh.
  11. 제9항에 있어서, 상기 (b)단계의 창이자는 가열하여 가시를 제거한 것인 제조방법.10. The method according to claim 9, wherein the window box of step (b) is removed by heating.
  12. 제9항에 있어서, 상기 (b)단계의 고삼은 고삼의 뿌리를 수세하고, 쌀뜨물에 침지한 후, 건조한 것인 제조방법.10. The method according to claim 9, wherein the ginseng of step (b) is washed with the roots of the ginseng, immersed in rice water, and dried.
PCT/KR2009/006960 2008-11-26 2009-11-25 Topical skin composition and method for preparing same WO2010062103A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0117872 2008-11-26
KR1020080117872A KR20100059188A (en) 2008-11-26 2008-11-26 Composition for external application to skin and preparation method thereof

Publications (3)

Publication Number Publication Date
WO2010062103A2 true WO2010062103A2 (en) 2010-06-03
WO2010062103A9 WO2010062103A9 (en) 2010-10-28
WO2010062103A3 WO2010062103A3 (en) 2010-12-16

Family

ID=42226248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006960 WO2010062103A2 (en) 2008-11-26 2009-11-25 Topical skin composition and method for preparing same

Country Status (2)

Country Link
KR (1) KR20100059188A (en)
WO (1) WO2010062103A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102406676A (en) * 2011-11-29 2012-04-11 宋爱民 Traditional Chinese medicine pulvis for treating infantile eczema
CN102973707A (en) * 2012-11-23 2013-03-20 王恩瀚 Drug composite for treating infantile eczema and preparation method thereof
CN103655788A (en) * 2013-12-11 2014-03-26 山东中大药业有限公司 Traditional Chinese medicine composition for treating dermatophytosis
CN103690656A (en) * 2013-12-13 2014-04-02 姜兴文 Traditional Chinese herbal medicine for treating tinea and preparation method thereof
CN104000917A (en) * 2014-06-06 2014-08-27 青岛市市立医院 Traditional Chinese medicine formula for treating eczema
CN110101717A (en) * 2019-05-28 2019-08-09 刘友君 A kind of outer wound medicine and preparation method thereof containing badger fat

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102631452A (en) * 2012-04-28 2012-08-15 济南康众医药科技开发有限公司 Medicinal composition for treating infantile eczema
KR102118540B1 (en) * 2017-12-28 2020-06-03 우용규 A.C.C. extracts having anti-inflammatory and antimicrobial effects and composition comprising it as an active ingredient
KR102079442B1 (en) * 2018-04-10 2020-02-19 주식회사 케이티앤지 Composition for alleviating Atopic dermatitis and the manufacturing method of the same
CN108888676B (en) * 2018-09-04 2022-03-22 柳州市妇幼保健院 Traditional Chinese medicine composition for treating eczema and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030011732A (en) * 2002-11-25 2003-02-11 미즈코리아 주식회사 Antibiotic and cosmetic compositions containing herb medicines
KR20030083269A (en) * 2002-04-20 2003-10-30 설명수 A soap which chiefly consists of badger fat and the manufacturing method
KR100499999B1 (en) * 1997-09-09 2005-09-15 주식회사 참 존 Free radical scavenging cosmetics containing Chang-zai extract
KR100875577B1 (en) * 2008-06-05 2008-12-23 김길순 Manufacturing method for cosmetic cream

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499999B1 (en) * 1997-09-09 2005-09-15 주식회사 참 존 Free radical scavenging cosmetics containing Chang-zai extract
KR20030083269A (en) * 2002-04-20 2003-10-30 설명수 A soap which chiefly consists of badger fat and the manufacturing method
KR20030011732A (en) * 2002-11-25 2003-02-11 미즈코리아 주식회사 Antibiotic and cosmetic compositions containing herb medicines
KR100875577B1 (en) * 2008-06-05 2008-12-23 김길순 Manufacturing method for cosmetic cream

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102406676A (en) * 2011-11-29 2012-04-11 宋爱民 Traditional Chinese medicine pulvis for treating infantile eczema
CN102973707A (en) * 2012-11-23 2013-03-20 王恩瀚 Drug composite for treating infantile eczema and preparation method thereof
CN103655788A (en) * 2013-12-11 2014-03-26 山东中大药业有限公司 Traditional Chinese medicine composition for treating dermatophytosis
CN103690656A (en) * 2013-12-13 2014-04-02 姜兴文 Traditional Chinese herbal medicine for treating tinea and preparation method thereof
CN104000917A (en) * 2014-06-06 2014-08-27 青岛市市立医院 Traditional Chinese medicine formula for treating eczema
CN110101717A (en) * 2019-05-28 2019-08-09 刘友君 A kind of outer wound medicine and preparation method thereof containing badger fat

Also Published As

Publication number Publication date
WO2010062103A3 (en) 2010-12-16
KR20100059188A (en) 2010-06-04
WO2010062103A9 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
WO2010062103A2 (en) Topical skin composition and method for preparing same
KR100755798B1 (en) A topical composition comprising extracts of feverfew tanacetum parthenium and method of treating and preventing inflammatory disorders using the composition
US9839663B2 (en) Formulations containing extracts of Echinacea angustifolia and Zingiber officinale which are useful in reducing inflammation and peripheral pain
WO2008140200A1 (en) External compositions for the skin
US20100120903A1 (en) Anti-inflammatory agent
WO2011105839A2 (en) External skin composition and a production method therefor
US20130337090A1 (en) Plant extracts for treating burns and chronic wounds
Gardiner Chamomile (Matricaria recutita, Anthemis nobilis)
WO2019083321A2 (en) Composition for antioxidation, anti-inflammation, or osteoclast differentiation inhibition
WO2018203668A1 (en) External-use skin preparation composition for alleviating atopic skin, and cosmetic containing same
WO2015030328A1 (en) Compositions for preventing or treating allergic skin disorders, containing gpcr19 agents as active ingredients
JPH02193930A (en) Radical eliminating agent
CN102114113B (en) Preparation method of Chinese pulsatilla root decoction granules
KR100483539B1 (en) Composition for preventing or treating atopic dermatitis and process for preparation thereof
WO2018111042A2 (en) Cosmetic composition comprising extract of medicinal herbs as active ingredient
KR20210150829A (en) Composition for treating of rhinitis comprising Angelica gigas extracts and indirubin
JPH01313435A (en) Gyuoseishin liquid and its production
WO2013115456A1 (en) Food, cosmetic material, or pharmaceutical composition containing ginger supercritical extract and fermented dropwort residue extract
KR100530843B1 (en) Anti-inflammatory composition containing paecilomyces extract and cordyceps extracts as effective composition
CN106822321B (en) Application of Curcuma water of traumatology in preparing medicine for treating keratosis pilaris
CN109674945A (en) The Chinese medicine composition and preparation method thereof of ulcer is cured in a kind of myogenic hemostasia and detumescence analgesic
JPH0327318A (en) Drug for allergic rhinitis
WO2013141565A1 (en) Composition for enhancing defenses of skin
KR20160043430A (en) Composition for preventing hair loss, promoting hair generation, or enhancing moist and glossy of hair and manufacturing method thereof
CN106729087A (en) A kind of Chinese medicine compound prescription external preparation for treating pruritus ani

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09829310

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09829310

Country of ref document: EP

Kind code of ref document: A2